2-[(Methoxycarbonyl)amino]-3-phenylprop-2-enoic acid | 88183-78-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-[(Methoxycarbonyl)amino]-3-phenylprop-2-enoic acid
• 英文别名: 2-(methoxycarbonylamino)-3-phenylprop-2-enoic acid
• CAS: 88183-78-2
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: OYYUVNYZWHJQLD-UHFFFAOYSA-N

物化性质

• 沸点：
  374.7±42.0 °C(Predicted)
• 密度：
  1.300±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(Methoxycarbonyl)amino]-3-phenylprop-2-enoic acid 在 C₆₀H₆₀P₂Rh⁽¹⁺⁾*ClO₄^(1-) 、 氢气 作用下， 以 四氢呋喃 为溶剂， 24.0 ℃ 、101.33 kPa 条件下， 反应 72.0h， 生成 N-methoxycarbonyl-L-phenylalanine
  参考文献：
  名称：

  Possible Origin of Electronic Effects in Rh(I)-Catalyzed Enantioselective Hydrogenation

  摘要：

  Reducing the electron density of ligands switches the regioselectivity of Rh(I)-catalyzed hydrometalation. A reversal of the sense of chiral induction was also observed when chiral ligands are electronically tuned in the same manner. The combined data provide an alternative rationale for the electronic effects often observed in asymmetric hydrogenation.

  DOI：

  10.1021/ja903089f

文献信息

• HIV PROTEASE INHIBITORS
  申请人：MCCAULEY John A.

  公开号：US20170217986A1

  公开（公告）日：2017-08-03

  The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z 1 , Z 2 , V 1 , V 2 , V 3 , R 6 , R 6A , and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  本发明涉及Formula (I)的2,6-吗啉衍生物及其药用盐，其中Z1、Z2、V1、V2、V3、R6、R6A和X在此被定义。该发明还涉及使用该发明的2,6-吗啉衍生物来抑制HV蛋白酶、抑制HV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病的发作或进展的方法。这些化合物及其盐可作为药物组合物中的成分使用，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• Catalytic, Asymmetric, and Stereodivergent Synthesis of Non-Symmetric β,β-Diaryl-α-Amino Acids
  作者：Carmela Molinaro、Jeremy P. Scott、Michael Shevlin、Christopher Wise、Alain Ménard、Andrew Gibb、Ellyn M. Junker、David Lieberman

  DOI：10.1021/ja511872a

  日期：2015.1.21

  concise, enantio- and diastereoselective route to novel nonsymmetrically substituted N-protected β,β-diaryl-α-amino acids and esters, through the asymmetric hydrogenation of tetrasubstituted olefins, some of the most challenging examples in the field. Stereoselective generation of an E- or Z-enol tosylate, when combined with stereoretentive Suzuki-Miyaura cross-coupling and enantioselective hydrogenation

  我们报告了一种简洁的对映选择性和非对映选择性途径，通过四取代烯烃的不对称氢化来制备新型非对称取代的 N-保护的 β,β-二芳基-α-氨基酸和酯，这是该领域最具挑战性的一些例子。E-或Z-烯醇甲苯磺酸酯的立体选择性生成，当与立体保留的 Suzuki-Miyaura 交叉偶联和由 (NBD)2RhBF4 和 Josiphos 配体催化的对映选择性氢化相结合时，可以完全控制两个邻位立体中心。对于各种 N-乙酰基、N-甲氧基羰基和 N-Boc β,β-二芳基脱氢氨基酸，获得了高产率和出色的对映选择性（高达 99% ee），
• US9994587B2
  申请人：——

  公开号：US9994587B2

  公开（公告）日：2018-06-12
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2015134366A1

  公开（公告）日：2015-09-11

  The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.